Aventis Completes the Divestment of Aventis Behring to CSL Limited
Aventis announced that the divestment of the therapeutic proteins business Aventis Behring to CSL Limited was completed on March 31, 2004. In this transaction, CSL Limited has acquired Aventis Behring, its subsidiaries and the plasma activities in Japan, previously held by Aventis Pharma Japan.
As previously announced, Aventis will receive total proceeds of up to US$925 million, consisting of a cash payment of US$550 million already received, as well as a total of US$125 million in deferred payments, which will be made in three installments: US$30 million on July 1, 2006; US$30 million on December 31, 2006; and a final payment of US$65 million on December 31, 2007. In addition, Aventis may receive up to US$250 million in an additional payment from CSL on the fourth anniversary of the closing of the transaction based on the performance of CSL's share price.
Other news from the department business & finance
Get the chemical industry in your inbox
From now on, don't miss a thing: Our newsletter for the chemical industry, analytics, lab technology and process engineering brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
